SCHEMBL2233362

SCHEMBL2233362

Brc1cc2c(s1)c1cc(Br)sc1c1cc(Br)sc21

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12345758 0.81 MAPT (0.33)
SCHEMBL14603456 0.79 EGFR (0.35)
SCHEMBL12712018 0.77
SCHEMBL24404197 0.77 GAA (0.32)
SCHEMBL1102387 0.77
SCHEMBL15260402 0.77 CYP3A4 (0.32) GSK3B
SCHEMBL10028812 0.75 GPR3 (0.36)
SCHEMBL19267320 0.73
SCHEMBL12711672 0.72
SCHEMBL28269421 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10113065-B1 Two-photon absorbing compounds and methods of making same GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE 2018-10-30 US disclosed
EP-3178823-A1 CHARGE TRANSPORTING MATERIAL FOR OPTOELECTRONIC AND/OR PHOTOELECTROCHEMICAL DEVICES Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) 2017-06-14 EP disclosed
EP-2361915-B1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF NIPPON KAYAKU KK (JP) 2015-01-28 EP disclosed
EP-2361915-B1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF NIPPON KAYAKU KK (JP) 2015-01-28 EP disclosed
US-8313671-B2 Heterocyclic compound and use thereof HIROSHIMA UNIVERSITY (JP) 2012-11-20 US disclosed
US-8313671-B2 Heterocyclic compound and use thereof HIROSHIMA UNIVERSITY (JP) 2012-11-20 US disclosed
US-8313671-B2 Heterocyclic compound and use thereof HIROSHIMA UNIVERSITY (JP) 2012-11-20 US disclosed
EP-2361915-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF Hiroshima University (JP) 2011-08-31 EP disclosed
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof HIROSHIMA UNIVERSITY (JP) 2011-08-25 US disclosed
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof HIROSHIMA UNIVERSITY (JP) 2011-08-25 US disclosed
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof HIROSHIMA UNIVERSITY (JP) 2011-08-25 US disclosed
WO-2010058833-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF 国立大学法人広島大学 (JP) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10113065-B1 Two-photon absorbing compounds and methods of making same TBXA2R, TBXAS1, TPD52L2 GSK3B 4858/4885
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof SCLY, C9, C1S GSK3B 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.